- Home
- AUTL vs KROS Comparison
AUTL vs KROS Comparison
Compare AUTL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- KROS
- Stock Information
- Founded
- AUTL 2014
- KROS 2015
- Country
- AUTL United Kingdom
- KROS United States
- Employees
- AUTL N/A
- KROS N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- KROS Health Care
- Exchange
- AUTL Nasdaq
- KROS Nasdaq
- Market Cap
- AUTL 625.4M
- KROS 558.9M
- IPO Year
- AUTL 2018
- KROS 2020
- Fundamental
- Price
- AUTL $2.41
- KROS $13.45
- Analyst Decision
- AUTL Strong Buy
- KROS Buy
- Analyst Count
- AUTL 5
- KROS 13
- Target Price
- AUTL $9.32
- KROS $20.63
- AVG Volume (30 Days)
- AUTL 2.1M
- KROS 603.2K
- Earning Date
- AUTL 08-07-2025
- KROS 08-06-2025
- Dividend Yield
- AUTL N/A
- KROS N/A
- EPS Growth
- AUTL N/A
- KROS N/A
- EPS
- AUTL N/A
- KROS 0.11
- Revenue
- AUTL $9,011,000.00
- KROS $214,713,000.00
- Revenue This Year
- AUTL $461.76
- KROS $5,006.76
- Revenue Next Year
- AUTL $112.66
- KROS N/A
- P/E Ratio
- AUTL N/A
- KROS $123.44
- Revenue Growth
- AUTL N/A
- KROS 91657.70
- 52 Week Low
- AUTL $1.11
- KROS $9.12
- 52 Week High
- AUTL $5.00
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- AUTL 70.63
- KROS 43.42
- Support Level
- AUTL $2.20
- KROS $13.24
- Resistance Level
- AUTL $2.44
- KROS $13.77
- Average True Range (ATR)
- AUTL 0.12
- KROS 0.38
- MACD
- AUTL -0.01
- KROS -0.04
- Stochastic Oscillator
- AUTL 84.95
- KROS 28.00
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.